ArticleStem cell research & therapy2026
PTGIS inhibited osteogenic and promoted angiogenic differentiation of bone marrow mesenchymal stem cells via endoplasmic reticulum stress mediated PI3K/AKT signaling.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMesenchymal stem cells (MSCs) play a key role in ectopic mineralization. Effective treatment requires both inhibiting pathological calcification and promoting vessel growth. While prostacyclin synthase (PTGIS) is critical for vascular health, its role in regulating osteogenic and angiogenic differentiation in MSCs remains unclear.
methodsFollowing PTGIS modulation in bone marrow mesenchymal stem cells (BMSCs), osteogenesis was assessed by alkaline phosphatase (ALP) activity, Alizarin Red staining (ARS), and hydroxyapatite/tricalcium phosphate (HA/TCP) particles implantation. Angiogenesis was evaluated via a co-culture system of BMSCs and human umbilical vein endothelial cells (HUVECs). Mechanistic studies involved Ca²⁺ dynamics, western blotting, and pharmacological inhibition.
resultsKnockdown of PTGIS enhanced ALP activity, mineralization, the expression of the osteogenic marker DMP1/BSP, and bone-like tissue formation both in vitro and in vivo. Conversely, PTGIS knockdown reduced tubule formation in vitro and impaired blood vessel formation, and the expression of the angiogenic marker CD31 in vivo. Mechanistically, the overexpression of PTGIS promoted Ca²⁺ efflux, endoplasmic reticulum (ER) dilation and vacuolization, increased the levels of the ER stress markers BIP/GRP75, and elevated PI3K/AKT phosphorylation. The inhibition of either ER stress or AKT activity restored osteogenic capacity by enhancing ALP activity and mineralization, and suppressed angiogenic capacity by inhibiting tubule formation in BMSCs.
conclusionPTGIS inhibited osteogenic and promoted angiogenic differentiation of BMSCs through ER stress mediated PI3K/AKT signaling pathway. This PTGIS-dependent regulatory pathway offers new insight into MSC fate determination and represents a potential therapeutic strategy for treating ectopic mineralization disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.